Article Text

SAT0204 The Eular Systemic Sclerosis Impact of Disease (ScleroID) Score – A New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis under Development
  1. R. Dobrota1,
  2. M. Becker2,
  3. K. Fligelstone3,
  4. J. Fransen4,
  5. A. Kennedy5,
  6. Y. Allanore6,
  7. P. Carreira7,
  8. L. Czirijak8,
  9. C. Denton9,
  10. R. Hesselstrand10,
  11. G. Sandqvist10,
  12. O. Kowal-Bielecka11,
  13. M. Matucci-Cerinic12,
  14. C. Mihai13,
  15. A. Gheorghiu13,
  16. U. Müller-Ladner14,
  17. M. Frerix14,
  18. T. Heiberg15,
  19. O. Distler1
  1. 1Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland
  2. 2Department of Rheumatology and Clinical Immunology, Charitè University Hospital, Berlin, Germany
  3. 3FESCA, Portsmouth, United Kingdom
  4. 4Division of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
  5. 5FESCA, Dublin, Ireland
  6. 6Rheumatology A Department, Cochin Hospital, Paris, France
  7. 7Division of Rheumatology, Hospital 12 de Octubre, Madrid, Spain
  8. 8Department of Immunology and Rheumatology, Faculty of Medicine, University of Pécs, Pécs, Hungary
  9. 9Centre for Rheumatology, Royal Free and University College London Medical School, Royal Free Campus, London, United Kingdom
  10. 10Department of Rheumatology, Lund University, Lund, Sweden
  11. 11Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
  12. 12Division of Rheumatology, University of Florence, Florence, Italy
  13. 13Department of Internal Medicine and Rheumatology, Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
  14. 14Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany
  15. 15Department of Health and Social Sciences, Oestfold University College, Oslo, Norway


Background Patient reported outcome measures (PROM) are required as key outcomes in disease modifying therapeutic trials in systemic sclerosis (SSc) and could also improve the clinical care of patients with SSc. A PROM tool for clinical trials and practice in SSc, covering the different features of this multi-organ autoimmune disease, is lacking.

Objectives To develop and validate a brief, disease-specific, patient-derived, composite disease impact score for scientific and clinical use in SSc.

Methods This multi-center project involves SSc patients and experts from 11 European countries. Firstly, using the nominal group technique, patients with SSc selected the health dimensions where the disease has the most significant impact. The dimensions were subsequently given numeric priority by an international group of SSc patients. The dimensions with the top 10 median ranks, as ranked by the patients, were used to construct the ScleroID questionnaire using numeric rating scales. Further, the dimensions are currently weighted by distributing 100 points among the dimensions by a larger cohort of patients from all participating countries. The calculation of the score will be based on the ranking of the weights.

Results 24 SSc patients selected 17 health dimensions in the nominal group exercise. The prioritization cohort included 108 SSc patients from 11 centers (female:male 82:25, limited:diffuse SSc subset 53:54). The top 10 health dimensions which were ranked most relevant by the patients were Raynaud's phenomenon, hand function, upper and lower gastrointestinal tract symptoms, pain, fatigue, limitation of life choices and activities, body mobility, breathlessness and digital ulcers (Figure 1).

Conclusions The EULAR ScleroID score is a novel tool under development designed for use in clinical practice and clinical trials to display the disease impact of SSc. Further validation of this new instrument will be performed as soon as the weighting procedure is completed.

Acknowledgement Contributing patients: Yanne Perriault, Susanne Tuppeck, Helene Kambourakis, Elisabeth Scheel, Stephan Houbertz, Anna Vegh, Beata Garay Toth, Barbara Zappitello, Grazia Tassini, Silvia Sandulescu, Ana Marcela Badea, Stefana Dumitru, Rachida Amrouch, Alicia García Oliva, Begoña María Gorricho Corta, Heleen Lever, Johanna Berglind, Mervat Gaafar, Natalie Perruchoud, Alice Martins Correia, Richard Dodds, Nicola Whitehill.

Disclosure of Interest R. Dobrota: None declared, M. Becker: None declared, K. Fligelstone: None declared, J. Fransen: None declared, A. Kennedy: None declared, Y. Allanore Grant/research support from: Bristol-Myers Squibb, Roche/Genentech, Inventiva, Pfizer, Sanofi, and Servier, Consultant for: Actelion, Bayer, Roche/Genentech, Inventiva, Medac, Pfizer, Sanofi, Servier, and UCB, P. Carreira: None declared, L. Czirijak: None declared, C. Denton: None declared, R. Hesselstrand: None declared, G. Sandqvist: None declared, O. Kowal-Bielecka: None declared, M. Matucci-Cerinic: None declared, C. Mihai: None declared, A. Gheorghiu: None declared, U. Müller-Ladner: None declared, M. Frerix: None declared, T. Heiberg: None declared, O. Distler Grant/research support from: Bayer, Sanofi, Ergonex, Boehringer Ingelheim, Actelion, Pfizer, Consultant for: 4 D Science, Actelion, Active Biotec, Bayer, BiogenIdec, BMS, Boehringer Ingelheim, EpiPharm, Ergonex, espeRare foundation, Genentech/Roche, GSK, Inventiva, Lilly, medac, MedImmune, Pharmacyclics, Pfizer, Serodapharm, Sinoxa

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.